April 7, 2020April 16, 2020
Publisher’s Note: Have IPF But Not Taking Meds? Take Our Survey.

Have you been diagnosed with idiopathic pulmonary fibrosis (IPF) but are not currently taking medication to treat the disease? You’re not alone. Recent ... Read more
June 3, 2020June 3, 2020
Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not ... Read more
June 2, 2020June 2, 2020
CHMP Favors EU Approval of Ofev for Progressive Fibrosing ILDs

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Ofev (nintedanib) for the treatment of ... Read more
June 1, 2020June 1, 2020
Blood Levels of Antioxidant Protein May Serve as IPF Biomarker

Low blood levels of haptoglobin-related protein (HRP), a protein with antioxidant properties, may serve as a biomarker of idiopathic pulmonary fibrosis (IPF), according to ... Read more
May 29, 2020May 27, 2020
6 People You Will Meet in an ICU Waiting Room

When I recall the times that loved ones were in the hospital for extended periods, I can still feel the energy of the waiting ... Read more
May 29, 2020May 29, 2020
Stem Cells Derived from Amniotic Membrane Slow Lung Scarring in IPF Mouse Model

Stem cells derived from the placental amniotic membrane — one of the membranes of the amniotic sac that surrounds a baby while it is ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

April 27, 2018April 27, 2018

Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests

News

Treatment with plant-derived aloperine reduces the severity of lung injury in a mouse model of pulmonary fibrosis, a new Chinese study reports. The research, “Aloperine Protects Mice against Bleomycin-induced Pulmonary Fibrosis by Attenuating Fibroblast Proliferation and Differentiation,” was published ... Read more

Publisher’s Note: Have IPF But Not Taking Meds? Take Our Survey.

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

CHMP Favors EU Approval of Ofev for Progressive Fibrosing ILDs

6 People You Will Meet in an ICU Waiting Room

Stem Cells Derived from Amniotic Membrane Slow Lung Scarring in IPF Mouse Model

Stem Cells Derived from Amniotic Membrane Slow Lung Scarring in IPF Mouse Model

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

How I Manage My Energy Reserves with Pulmonary Fibrosis

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Ofev Approved in US and Canada for Progressive Fibrosing ILDs

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

Subscribe to our mailing list

In Certain IPF Patients with Lung Cancer, Ofev May Be Best Treatment

I Have COVID-19. Here’s What Happened

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

FDA Names AMP945, Potential IPF Treatment, an Orphan Drug

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Repeat Hospitalizations in IPF Patients Linked to Poor Survival in Study

Setanaxib Phase 1 Trial Approved in France for Testing in Healthy Volunteers

Dear Christie: A Letter to a New Caregiver

Lung CT Scans May Help Predict Mortality Risk of IPF Patients

Honoring a Patient’s Knowledge of Their Own Disease

Restless Legs Syndrome Prevalent in IPF Patients, Study Finds

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

Phase 2 Trial of Inhaled IPF Therapy Enrolling as Planned, Galecto Says

Algernon Gets Nod to Launch Phase 2 IPF Trial of NP-120 in Australia

Honoring One Year of ‘Courage to Care’

Potential IPF Inhalation Treatment, GB0139, Shows Ability to Slow Progression

Loss of NEDD4-2 Triggers IPF in Adult Mice, Study Finds

Severe Fatigue Common in Patients With IPF, Pulmonary Sarcoidosis, Study Suggests

Study Links IPF Mortality to Mechanical Ventilation After High-flow Nasal Cannula Oxygen Therapy

I’m Feeling Bad — and That’s Good

Avalyn Raises $35.5M to Support Trials of Inhaled Pirfenidone for IPF, CLAD

Why I’m Feeling Grateful During the COVID-19 Pandemic

NORD Webinar Outlines COVID-19 Response on Financial, Policy Fronts

Life After COVID-19: Here’s What I Think Will Change

Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests

Pin It on Pinterest

Publisher’s Note: Have IPF But Not Taking Meds? Take Our Survey.

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

CHMP Favors EU Approval of Ofev for Progressive Fibrosing ILDs

Blood Levels of Antioxidant Protein May Serve as IPF Biomarker

6 People You Will Meet in an ICU Waiting Room

Stem Cells Derived from Amniotic Membrane Slow Lung Scarring in IPF Mouse Model

Stem Cells Derived from Amniotic Membrane Slow Lung Scarring in IPF Mouse Model

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

How I Manage My Energy Reserves with Pulmonary Fibrosis

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Ofev Approved in US and Canada for Progressive Fibrosing ILDs

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

Subscribe to our mailing list

In Certain IPF Patients with Lung Cancer, Ofev May Be Best Treatment

I Have COVID-19. Here’s What Happened

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

FDA Names AMP945, Potential IPF Treatment, an Orphan Drug

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Repeat Hospitalizations in IPF Patients Linked to Poor Survival in Study

Setanaxib Phase 1 Trial Approved in France for Testing in Healthy Volunteers

Dear Christie: A Letter to a New Caregiver

Lung CT Scans May Help Predict Mortality Risk of IPF Patients

Honoring a Patient’s Knowledge of Their Own Disease

Restless Legs Syndrome Prevalent in IPF Patients, Study Finds

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

Phase 2 Trial of Inhaled IPF Therapy Enrolling as Planned, Galecto Says

Algernon Gets Nod to Launch Phase 2 IPF Trial of NP-120 in Australia

Honoring One Year of ‘Courage to Care’

Potential IPF Inhalation Treatment, GB0139, Shows Ability to Slow Progression

How I Selectively Share Updates About My PF Experience

Loss of NEDD4-2 Triggers IPF in Adult Mice, Study Finds

Severe Fatigue Common in Patients With IPF, Pulmonary Sarcoidosis, Study Suggests

Study Links IPF Mortality to Mechanical Ventilation After High-flow Nasal Cannula Oxygen Therapy

I’m Feeling Bad — and That’s Good

Avalyn Raises $35.5M to Support Trials of Inhaled Pirfenidone for IPF, CLAD

Why I’m Feeling Grateful During the COVID-19 Pandemic

NORD Webinar Outlines COVID-19 Response on Financial, Policy Fronts

Life After COVID-19: Here’s What I Think Will Change

Pin It on Pinterest